“`html
On October 31, 2025, Needham reaffirmed a Buy recommendation for Gilead Sciences (NasdaqGS:GILD), with an average one-year price target of $129.72 per share, suggesting an 8.29% upside from its latest closing price of $119.79. The price target range spans from $101.00 to $150.15.
Institutional ownership increased by 83 funds, totaling 3,396, as of the last quarter. Total shares owned rose by 0.47% to 1,294,184K shares, with an average portfolio weight of 0.45%. The projected annual revenue is estimated at $27,582 million, reflecting a 5.17% decline.
Capital World Investors saw a 15.65% decrease in shares, while Wellington Management Group increased its holding by 27.10%. The overall put/call ratio stands at 0.62, indicating a bullish sentiment towards GILD.
“`
